Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522663

Integrated Approach to Pediatric bronchiolitis Control: Role of Respiratory Professionals, Nursing Care, Imaging Support, Primary Care, Pharmacotherapy, and Public Health Surveillance

Abdullah Mastour Alamar [(1)] , Amwaj Qassem alqahtani [(2)] , Abduljalil salah Alahmadi [(3)] , Ahmed Mohammed Masrhi [(4)] , Mohammad Omar Mohammad Sultan [(4)] , Ali Mohammed Ali Qaysi [(5)] , Kheder Moussa Yahia Gabarri [(5)] , Tariq Ahmed Hamoud Al Khairat [(6)] , Hana Saeed Faqih [(7)]

(1) Diriyah Hospital,Ministry Of Health, Saudi Arabia,
(2) Ministry of Health, Saudi Arabia,
(3) Medical Waste Management Department,Ministry Of Health, Saudi Arabia,
(4) Sabya General Hospital, Jazan Region, Ministry of Health, Saudi Arabia,
(5) Samtah General Hospital, Jazan Region, Ministry of Health, Saudi Arabia,
(6) Pharmaceutical Care Services, Samtah General Hospital, Jazan Region, Ministry of Health, Saudi Arabia,
(7) Prince Faisal Bin Khalid Cardiac Center,Ministry Of Health, Saudi Arabia

Abstract

Background: Pediatric bronchiolitis is among the most common respiratory illnesses affecting infants, primarily caused by respiratory syncytial virus (RSV), with significant clinical and economic burden during seasonal surges.
Aim: To summarize the etiology, epidemiology, clinical features, management strategies, preventive interventions, and complications associated with pediatric bronchiolitis.
Methods: A comprehensive review of clinical, epidemiological, and pathophysiological information extracted from recent literature detailing viral causes, risk factors, clinical progression, diagnostic practices, and treatment approaches.
Results: Bronchiolitis primarily affects infants aged two to six months and is influenced by host, environmental, and social risk factors such as prematurity, congenital heart disease, tobacco smoke exposure, and overcrowding. Diagnosis remains clinical, while management focuses on hydration, oxygen therapy, secretion clearance, and symptom monitoring. Preventive measures—including maternal RSV vaccination and infant monoclonal antibody administration—significantly reduce hospitalization and severe disease burden.
Conclusion: Bronchiolitis is typically self-limiting but may progress rapidly in high-risk infants. Early recognition, supportive care, and expanded preventive strategies remain essential to reducing morbidity.
Keywords: Bronchiolitis; RSV; Pediatrics; Management; Epidemiology; Prevention; Immunization.

Introduction

Pediatric bronchiolitis represents an acute infection of the lower respiratory tract that predominantly affects infants and young children, with viral pathogens identified as the principal etiological agents. It is recognized as one of the most frequently encountered respiratory illnesses in children aged two years and younger and remains the foremost cause of hospital admission within this vulnerable age group. The condition imposes a substantial clinical and economic burden on healthcare systems, particularly during seasonal viral peaks, when pediatric services experience marked increases in emergency visits and inpatient admissions. The diagnosis of bronchiolitis is largely established on clinical grounds, relying on a comprehensive assessment of history and physical examination findings rather than routine laboratory confirmation. However, in cases characterized by severe clinical presentation or the need for hospitalization, viral testing may be warranted. Identification of the causative pathogen in such settings contributes to targeted infection prevention strategies, supports appropriate cohorting of patients, and reduces the risk of nosocomial transmission within pediatric units. Although a considerable proportion of hospitalized infants present with identifiable risk factors that predispose them to severe disease, including prematurity or underlying medical conditions, it is important to acknowledge that previously healthy infants and even older children may also experience significant disease progression requiring inpatient management. In its most critical form, bronchiolitis can lead to profound respiratory distress and failure, necessitating advanced respiratory support, including mechanical ventilation in intensive care settings [1]. Respiratory syncytial virus (RSV) is recognized as the predominant causative agent of bronchiolitis; nevertheless, a wide spectrum of respiratory viruses has been implicated in the pathogenesis of the disease among infants and young

*Corresponding author e-mail: MMA-220@hotmail.com (Abdullah Mastour Alamar Alamar).
Receive Date: 07 December 2025, Revise Date: 29 December 2025, Accept Date: 31 December 2025

children. The global burden associated with RSV bronchiolitis is considerable, with current estimates indicating approximately 33 million cases annually, of which nearly 95% occur in low-income countries. The impact on healthcare systems is further underscored by data suggesting that around 3.6 million infants require hospitalization for bronchiolitis each year. Mortality remains a significant concern, with up to 118,000 deaths attributed directly to the condition or its complications. Alarmingly, nearly half of these fatalities occur during the first six months of life, and approximately 97% of all infant deaths related to bronchiolitis are reported in low- and middle-income countries [1]. These figures highlight the persistent global disparities in access to preventive measures, timely diagnosis, and supportive care, reinforcing the urgent need for strengthened public health strategies and equitable healthcare delivery.

Etiology

Respiratory syncytial virus remains the principal etiological agent responsible for acute bronchiolitis in pediatric populations, accounting for nearly two thirds of documented cases. Its predominance is consistent across diverse geographic regions and healthcare settings, reinforcing its central role in the pathogenesis of lower respiratory tract infections during infancy and early childhood. In addition to RSV, other viral pathogens contribute substantially to disease incidence. Human metapneumovirus and parainfluenza virus type 3 collectively account for approximately half of the remaining cases, highlighting the multifactorial viral landscape underlying this condition. These pathogens share similar modes of transmission and seasonal patterns, often co-circulating during peak respiratory infection periods and compounding the burden on pediatric healthcare services. The epidemiological profile of bronchiolitis underwent notable shifts during the COVID-19 pandemic. A limited number of bronchiolitis cases associated with SARS-CoV-2 infection were documented, while hospital admissions related to RSV bronchiolitis declined markedly. This reduction has been attributed to widespread public health interventions, including social distancing measures, enhanced hygiene practices, and reduced interpersonal contact. However, following the relaxation of pandemic-related restrictions, a resurgence of RSV infections was observed, with RSV once again emerging as the dominant causative agent of bronchiolitis [2]. This rebound effect underscores the dynamic interplay between viral transmission patterns and population-level immunity, as well as the sensitivity of RSV epidemiology to environmental and behavioral factors.



Fig. 1: Bronchitis Vs. Bronchiolitis.

Although RSV remains the leading pathogen implicated in bronchiolitis, a broad spectrum of additional respiratory viruses has been identified as potential contributors. These include adenoviruses, bocaviruses, coronaviruses such as SARS-CoV-2, enteroviruses, human metapneumovirus, influenza viruses, measles virus, and rhinoviruses [3][4]. While these agents are less frequently associated with classic bronchiolitis compared with RSV, their clinical manifestations may overlap significantly, often presenting with wheezing, cough, and respiratory distress. In certain instances, atypical bacterial pathogens such as Mycoplasma pneumoniae have been linked to bronchiolitis-like syndromes characterized predominantly by wheezing, further broadening the differential etiological considerations. The expanding availability of antiviral therapies, immunomodulatory agents, and pathogen-specific preventive strategies has heightened the importance of accurate etiological identification. Determining the causative organism is particularly critical in severely ill or high-risk children, where targeted therapeutic decisions may influence disease progression and clinical outcomes. Precise diagnosis facilitates optimized infection control measures, rational antimicrobial stewardship, and appropriate allocation of healthcare resources. Consequently, etiological clarification has evolved from a predominantly epidemiological interest to a clinically relevant component of comprehensive bronchiolitis management, particularly in intensive care and high-dependency settings.

Epidemiology

Bronchiolitis represents one of the most prevalent respiratory illnesses affecting infants and young children on a global scale and is widely recognized as a clinical syndrome primarily confined to this age group [1]. The condition is typically defined by acute onset of wheezing and tachypnea in association with manifestations of viral upper respiratory tract infection, including cough, nasal congestion, and rhinorrhea. Although it may occur throughout the first two years of life, the highest incidence is observed among infants between two and six months of age. This age predilection reflects developmental vulnerability of the lower airways,

limited pulmonary reserve, and immature immune responses, all of which contribute to increased susceptibility and disease severity during early infancy. The clinical spectrum of bronchiolitis is broad and ranges from mild disease characterized by wheezing and moderately increased respiratory rate to severe respiratory compromise requiring intensive care support. Some infants present as relatively stable despite audible wheezing, a presentation sometimes referred to as the "happy wheezer," whereas others develop marked respiratory distress with nasal flaring, intercostal retractions, hypoxemia, and progressive fatigue. In the most severe cases, respiratory failure may ensue, necessitating endotracheal intubation and mechanical ventilation. This variability in presentation underscores the importance of vigilant clinical assessment, especially in young infants, in whom deterioration can occur rapidly. Early identification of severe disease and prompt supportive management remain central to reducing complications and improving clinical outcomes.

Bronchiolitis demonstrates distinct seasonal patterns that vary according to geographic and climatic conditions. In temperate regions, annual outbreaks typically occur during the fall and winter months and coincide with the circulation of other respiratory viruses [1][5]. In contrast, subtropical and tropical regions often experience bronchiolitis throughout the year, with increased incidence during the rainy season. Desert climates show a more restricted seasonal window, with most cases clustered in winter and minimal activity during other periods [1][5]. Environmental determinants such as ambient temperature, humidity, and ultraviolet-B radiation have been proposed as contributing factors influencing viral survival and transmission dynamics. Despite these associations, the precise mechanisms underlying global seasonal variability remain incompletely understood, and further epidemiological research is required to clarify these complex interactions [5]. The transmission characteristics of respiratory viruses implicated in bronchiolitis also shape its epidemiology. Many causative viruses have short incubation periods, commonly ranging from two to three days. In older children and adults, viral shedding is generally limited to a brief duration of several days. However, in infants, young children, and immunocompromised individuals, viral shedding may persist for more than four weeks [6]. This prolonged shedding presents challenges for infection control in both hospital and community settings and complicates the interpretation of polymerase chain reaction diagnostics. Detection of viral nucleic acid may reflect residual shedding from a recent infection rather than active disease, potentially confounding clinical decision-making and surveillance data.

The risk of severe bronchiolitis is influenced by a complex interplay of host, environmental, and social determinants [7][8][9][10]. Host-related factors include prematurity, low birth weight, chronic lung disease such as bronchopulmonary dysplasia, asthma, or cystic fibrosis, and hemodynamically significant congenital heart disease, particularly lesions associated with left-to-right shunting. Additional vulnerability is observed among infants younger than three months of age, those with immunodeficiency, Down syndrome, neuromuscular disorders, or other chronic medical conditions. Environmental exposures further modify risk, with tobacco smoke and indoor or outdoor air pollutants contributing to airway inflammation and impaired mucociliary clearance. Residence at high altitudes above 2500 meters has also been associated with increased disease severity, possibly due to reduced oxygen tension. Social determinants play a substantial role in transmission dynamics, including the presence of older siblings, attendance at daycare, living in crowded households, and twin or multiple gestation status. Recognition of these interrelated risk factors is essential for targeted prevention strategies, early clinical monitoring, and prioritization of high-risk populations for prophylactic interventions and enhanced surveillance.

Pathophysiology

The pathophysiological process of bronchiolitis begins with viral entry through mucosal surfaces of the nasopharynx, oral cavity, or conjunctiva, reflecting the primary routes of transmission for most respiratory viruses. Following inoculation, viral replication initially occurs within the epithelial cells of the nasopharynx. In the case of respiratory syncytial virus, which represents the most common etiological agent, replication at this upper airway site precedes extension to the lower respiratory tract. Viral dissemination occurs through aspiration of infected secretions and direct cell-to-cell spread, allowing the pathogen to reach the terminal bronchioles within approximately one to three days after the onset of upper respiratory symptoms. RSV demonstrates a predilection for infecting type I alveolar pneumocytes, with limited involvement of type II pneumocytes, while largely sparing basal epithelial cells. This selective cellular tropism contributes to disruption of the alveolar-capillary interface and impairs gas exchange. As viral replication progresses in the epithelial lining of the small airways, direct cytopathic effects lead to cellular injury and death. Simultaneously, the host immune response is activated. Infected epithelial cells release proinflammatory cytokines and chemokines, initiating a cascade that amplifies local inflammation. The inflammatory milieu promotes increased vascular permeability, resulting in interstitial and submucosal edema. It also stimulates goblet cell hyperactivity and mucus hypersecretion, which together narrow the already small bronchiolar lumen [11].

The accumulation of mucus, combined with sloughed necrotic epithelial cells and infiltrating inflammatory cells, contributes to intraluminal obstruction of the terminal bronchioles. Infants are particularly vulnerable to this obstructive process due

to the inherently small diameter of their airways. Even minimal mucosal swelling or debris can significantly increase airflow resistance according to Poiseuille's principles, leading to turbulent airflow and the characteristic wheezing observed clinically. Partial airway obstruction permits air entry during inspiration but impedes effective expiration, resulting in air trapping and hyperinflation. In contrast, complete obstruction may lead to distal collapse of alveoli and segmental atelectasis. These ventilation abnormalities create mismatched ventilation-perfusion ratios, contributing to hypoxemia and variable degrees of respiratory distress. Histopathological examination of affected lung tissue reveals necrosis of bronchiolar epithelial cells accompanied by regenerative proliferation of the bronchiolar epithelium. The inflammatory response is characterized by infiltration of monocytes and T lymphocytes within the bronchiolar walls and surrounding pulmonary arterioles. Neutrophilic infiltration is also frequently observed between vascular structures and small airways, reflecting the intensity of the acute inflammatory response [12][13]. Bronchoalveolar lavage studies in pediatric patients commonly demonstrate neutrophilia, further supporting the prominent role of innate immune activation in disease progression [14]. The combined effects of epithelial necrosis, inflammatory cell infiltration, mucosal edema, and mucus accumulation lead to marked narrowing of the bronchiolar lumen. This obstruction increases airway resistance and disrupts normal airflow dynamics. As resistance rises, the work of breathing escalates, placing substantial physiological strain on infants who possess limited respiratory muscle endurance. Progressive fatigue may ensue in severe cases, potentially culminating in respiratory failure if supportive interventions are not instituted promptly. Overall, the pathophysiology of bronchiolitis reflects a complex interaction between direct viral cytotoxicity and host immune responses within the small airways. The structural and functional characteristics of the infant respiratory system amplify the clinical impact of these processes, explaining the heightened susceptibility and severity observed in early life.

History and Physical

Infants with bronchiolitis generally present with a predictable constellation of symptoms identified through history and physical examination. Early in the course of illness, caregivers often report manifestations consistent with an upper respiratory viral infection, including cough, nasal congestion, and rhinorrhea, occasionally accompanied by low-grade fever as viral replication predominantly occurs in the nasopharynx. Parents frequently note a progression from mild cold-like symptoms to more concerning respiratory changes, describing episodes of "breathing funny" or rapid breathing, difficulties in feeding, or bluish discoloration of the lips and nailbeds. Observations of nasal flaring and intercostal retractions are common, reflecting the infant's effort to maintain adequate ventilation in the face of airway obstruction. On clinical examination, infants may exhibit a combination of low-grade fever, tachypnea, and hypoxemia. Respiratory rates exceeding 100 breaths per minute are frequently observed, contributing to feeding intolerance and increased metabolic demand. Pulse oximetry often reveals varying degrees of hypoxemia secondary to mucous plugging and atelectasis, producing a ventilation-perfusion mismatch that can compromise oxygen delivery [15]. Cyanosis of the lips and nail beds may be evident, particularly during periods of increased respiratory effort.

Physical assessment typically demonstrates grunting, nasal flaring, intercostal and subcostal retractions, and abdominal breathing. Auscultation often reveals diffuse wheezing on both inspiration and expiration, reflecting small airway obstruction characteristic of viral bronchiolitis. Infants appearing fatigued, pale, or with poor air entry warrant immediate attention, as these signs may indicate impending respiratory failure. Such presentations necessitate prompt escalation of care, including consideration for intubation and mechanical ventilation to prevent further deterioration. The combination of caregiver-reported symptoms and objective findings on examination provides critical guidance for early recognition, risk stratification, and timely intervention in infants affected by bronchiolitis. This approach allows clinicians to identify those at risk for severe disease, optimize supportive care, and prevent complications associated with respiratory compromise.

Evaluation

Bronchiolitis is predominantly a clinical diagnosis, relying on a detailed history of the current illness and careful assessment of physical signs. Evaluation begins with an understanding of symptom progression, including the onset of cough, congestion, rhinorrhea, and any episodes of fever. Clinical severity is most accurately gauged through observation of the infant's overall condition, including respiratory effort, oxygenation status, and feeding behavior. Oxygen saturation, measured via pulse oximetry, is an essential metric for determining the need for supplemental oxygen and the potential requirement for hospital admission. Infants unable to maintain adequate oral intake due to coughing, labored breathing, or sputtering during feeding are at increased risk of dehydration and may require intravenous fluids and inpatient monitoring. Feeding ability remains one of the most sensitive indicators of disease severity and guides timely escalation of care. Tachypnea exceeding 60 breaths per minute or oxygen saturation levels below 92% are widely accepted thresholds for considering hospitalization. Continuous monitoring of respiratory effort, including observation for nasal

flaring, intercostal retractions, and grunting, complements objective measures and helps identify infants at risk of respiratory deterioration. In cases where moderate respiratory compromise is present, a trial of aerosolized bronchodilators such as albuterol may be administered to evaluate responsiveness [16]. However, this intervention is generally reserved for patients demonstrating significant airway obstruction or underlying reactive airway disease. Infants who exhibit signs of clinical fatigue, persistent hypoxemia, or impending respiratory failure should be assessed promptly for endotracheal intubation and mechanical ventilation to ensure adequate oxygen delivery and prevent further decompensation.

Laboratory evaluation may include attempts at viral identification using commercially available assays. Techniques such as nucleic acid amplification testing, immunofluorescence, and enzyme immunoassay allow for the detection of viral RNA or antigens in nasopharyngeal or other respiratory samples. Identifying the causative pathogen can refine the diagnostic workup, inform infection control strategies, and assist in decisions regarding patient cohorting within healthcare facilities. Although these tests do not typically alter the immediate supportive management of bronchiolitis, they provide valuable epidemiological information and help reduce the risk of nosocomial transmission. Radiographic imaging is generally discouraged unless alternative diagnoses are strongly suspected. Chest x-rays frequently demonstrate nonspecific findings, including hyperinflation, interstitial infiltrates, and peribronchial thickening, which do not reliably differentiate viral bronchiolitis from other respiratory conditions. Routine imaging may lead to unnecessary interventions or antibiotic use without improving clinical outcomes. Careful reliance on clinical assessment and selective use of diagnostic tests ensures appropriate management while minimizing unnecessary procedures, optimizing resource utilization, and supporting evidence-based care for infants with bronchiolitis.

Treatment / Management

Management of bronchiolitis remains predominantly supportive, with a focus on maintaining hydration, relieving airway obstruction, and monitoring for respiratory deterioration. Ensuring adequate fluid intake is critical, particularly in infants with feeding difficulties or increased insensible water losses due to tachypnea. Oral hydration is preferred when tolerated, but intravenous fluids are indicated in cases of poor oral intake, persistent vomiting, or significant dehydration. Suctioning of the upper airway using a bulb syringe or low-pressure mechanical suction is often required to remove secretions that obstruct airflow and exacerbate respiratory distress. Continuous monitoring of vital signs, particularly respiratory rate and oxygen saturation, allows for early detection of worsening respiratory function. Infants with oxygen saturation below 92% while breathing room air should receive supplemental oxygen, with continuous pulse oximetry recommended for hospitalized patients to guide ongoing therapy. Fever management with antipyretics such as acetaminophen or ibuprofen is appropriate when indicated, as hyperthermia may worsen dehydration and respiratory effort. The routine use of bronchodilators remains controversial; however, a monitored trial of aerosolized albuterol can be considered in infants exhibiting significant airway obstruction or severe respiratory compromise [16]. Glucocorticoids and racemic epinephrine have not demonstrated consistent efficacy in altering the clinical course of viral bronchiolitis and are therefore not recommended. Antibiotic therapy is reserved strictly for cases in which bacterial co-infection is confirmed or strongly suspected, as indiscriminate use offers no benefit and contributes to antimicrobial resistance.

Targeted antiviral therapy is indicated when specific viral pathogens are identified. For infants with confirmed influenza, oseltamivir (Tamiflu™) is recommended, particularly if initiated within 48 hours of symptom onset, as early administration improves viral clearance and may reduce illness severity. Similarly, in cases of SARS-CoV-2 infection, nirmatrelvir-ritonavir (Paxlovid™) may be considered for infants who meet age and clinical criteria, although use in this population remains guided by evolving evidence and regulatory recommendations. While therapeutic options exist, prevention remains the most effective strategy in reducing the morbidity associated with bronchiolitis. Historically, palivizumab (Synagis™), a monoclonal antibody directed against the F protein of RSV, was administered monthly during the RSV season to high-risk infants. This intervention reduced the risk of severe RSV disease but was not indicated for otherwise healthy infants during the first three months of life, who represent a substantial proportion of RSV-related hospitalizations. Recent advances have expanded preventive options. Maternal vaccination with the RSV vaccine (Abrysvo™) during pregnancy provides passive immunity to the newborn, while nirsevimab (Beyfortus™), a long-acting monoclonal antibody administered to infants at the onset of their first RSV season, offers direct protection for those whose birth parent did not receive the vaccine [17]. Both approaches have demonstrated efficacy in reducing severe RSV disease, hospitalization rates, and healthcare utilization. Availability and administration guidelines for these interventions may vary by region, and clinicians are advised to consult local protocols to ensure optimal use.

Influenza and SARS-CoV-2 vaccination strategies complement RSV preventive measures. Although these viruses contribute less substantially to bronchiolitis than RSV, immunization remains critical to reducing overall respiratory disease burden. Age-appropriate vaccination for all infants and children is

recommended by professional societies, including the American Academy of Pediatrics. For infants not yet eligible for vaccination, immunizing household members and close contacts serves as an effective indirect protective strategy, limiting viral transmission and reducing the likelihood of severe illness in vulnerable populations. Comprehensive management of bronchiolitis integrates supportive care, judicious use of targeted interventions, and proactive preventive strategies. Clinicians must individualize treatment plans based on disease severity, patient age, comorbidities, and resource availability while maintaining vigilance for signs of respiratory failure. By combining early recognition, evidence-based supportive therapies, pathogen-specific interventions, and preventive measures, healthcare providers can optimize outcomes, minimize complications, and reduce the burden of bronchiolitis in infants and young children [17].

Differential Diagnosis

The differential diagnosis of bronchiolitis encompasses several conditions that can present with overlapping respiratory symptoms in infants and young children. Gastroesophageal reflux may mimic bronchiolitis when acidic or non-acidic gastric contents are aspirated into the airway, causing cough, wheezing, and feeding difficulties. Distinguishing reflux-related respiratory symptoms from viral bronchiolitis relies on careful history-taking, including episodes of regurgitation, positional exacerbation, and temporal association with feeding. Aspiration pneumonia represents another potential mimic, particularly in infants with impaired swallowing, neurological disorders, or anatomical abnormalities of the upper gastrointestinal tract. Clinical features often include persistent cough, fever, localized lung findings, and radiographic infiltrates. Unlike bronchiolitis, aspiration pneumonia may demonstrate focal consolidation on imaging rather than diffuse wheezing and hyperinflation. Foreign body aspiration into the lower airway should be considered in infants presenting with sudden-onset respiratory distress, localized wheezing, or unilateral decreased breath sounds. History of choking or exposure to small objects may be elicited, and diagnosis may require imaging or bronchoscopy for confirmation. Congenital malformations such as vascular rings or slings can compress the trachea or esophagus, producing chronic stridor, recurrent respiratory infections, or feeding difficulties. These structural anomalies often present with persistent or progressive symptoms beyond the typical viral illness course and may require advanced imaging for diagnosis. Acute exacerbation of asthma, although less common in infants, can mimic bronchiolitis through wheezing, tachypnea, and increased work of breathing. Family history, response to bronchodilators, and recurrent episodes can aid differentiation. Finally, acute anaphylaxis, while rare in this age group, may present with respiratory compromise including wheezing, airway edema, and hypoxemia. Rapid onset following allergen exposure and systemic signs such as urticaria or hypotension distinguish it from viral bronchiolitis [17]. Accurate differentiation among these conditions is essential for guiding appropriate management, preventing complications, and ensuring timely intervention.

Prognosis

The prognosis of bronchiolitis in infants is typically favorable, with most cases resolving spontaneously within five to seven days. Clinical recovery generally coincides with the clearance of viral infection and the reduction of airway inflammation. Despite the generally benign course, some studies have suggested a potential association between early-life bronchiolitis and the later development of asthma. However, the overall incidence of asthma following bronchiolitis remains low, and the majority of affected children do not develop long-term respiratory disease. Risk factors that may predispose certain infants to subsequent asthma include a personal history of recurrent wheezing during early childhood and a family history of asthma, allergic rhinitis, or atopic dermatitis. These factors suggest an underlying atopic predisposition that may amplify susceptibility to airway hyperreactivity following viral insult [18]. Additional prognostic considerations include the age of the infant at the time of infection and the presence of comorbidities. Infants under three months of age, particularly those born prematurely or with underlying cardiopulmonary or immunologic disorders, may experience a more severe course and prolonged recovery. Close clinical monitoring is essential in these populations, as they are more prone to complications requiring hospitalization. Nevertheless, for the majority of otherwise healthy infants, supportive care, including hydration, oxygen supplementation when necessary, and careful monitoring of feeding and respiratory function, leads to complete recovery. Understanding the natural course of bronchiolitis and identifying children at higher risk of adverse outcomes allows clinicians to tailor follow-up and counseling, ensuring both short-term safety and long-term respiratory health. Overall, bronchiolitis remains a self-limiting illness for most infants, with excellent long-term outcomes in the absence of significant comorbidities [18].

Complications

Although uncommon, complications from bronchiolitis can be severe and may necessitate intensive medical intervention, particularly in vulnerable populations such as premature infants or those with underlying cardiopulmonary or immunocompromised conditions. Even in otherwise healthy infants, complications can occur, though the majority recover without incident [19][20][21][22][23]. Acute complications include

aspiration events, which may result from impaired swallowing during periods of increased respiratory effort. Aspiration can exacerbate respiratory distress, trigger secondary bacterial infections, and increase the need for supportive care, including oxygen therapy or mechanical ventilation. Respiratory failure is another significant acute complication and can arise from progressive airway obstruction, hypoxemia, and fatigue. Infants presenting with poor feeding, lethargy, or persistent hypoxemia require prompt evaluation and may need endotracheal intubation with mechanical ventilation to prevent irreversible hypoxic injury. Apnea is particularly concerning in very young infants or those born prematurely, often manifesting as intermittent pauses in breathing that may be accompanied by cyanosis or bradycardia. Secondary bacterial infections, though relatively rare, can complicate the course of bronchiolitis, necessitating antibiotic therapy when confirmed. In extreme cases, bronchiolitis can lead to death, underscoring the importance of early recognition and aggressive supportive care in high-risk patients. Chronic complications, while less frequent, can have longer-term implications for respiratory health. Recurrent episodes of wheezing may persist following an initial bronchiolitis infection, particularly in infants with an atopic background or a genetic predisposition to asthma. In rare instances, bronchiolitis obliterans may develop, characterized by irreversible airway obstruction due to fibrosis and inflammation of the small airways. This condition can lead to persistent respiratory symptoms, reduced pulmonary function, and the need for long-term medical management. Recognition of both acute and chronic complications is essential for guiding appropriate clinical monitoring, patient education, and preventive strategies. Clinicians must remain vigilant for early signs of deterioration, particularly in high-risk infants, to ensure timely intervention and to mitigate long-term sequelae [22][23].

Patient Education

Patient education is a critical component of bronchiolitis prevention and overall respiratory health in infants. Healthcare providers should emphasize the importance of age-appropriate vaccinations, including influenza, SARS-CoV-2, and RSV, as these interventions reduce the risk of severe viral infections that contribute to bronchiolitis. For RSV prevention, strategies include immunization of the pregnant parent to confer passive immunity to the infant and the administration of nirsevimab, a long-acting monoclonal antibody, once during the infant's first RSV season. These measures have been shown to significantly reduce the incidence of severe RSV disease and related hospitalizations in high-risk and otherwise healthy infants. For infants who are too young to receive vaccines directly, it is essential that household members and other close contacts maintain up-to-date immunizations. Ensuring that family and caregivers are protected against influenza, SARS-CoV-2, and RSV decreases the likelihood of viral transmission to the infant. Parents should be counseled on effective infection control practices, including frequent handwashing, minimizing contact with individuals exhibiting respiratory symptoms, and maintaining a smoke-free and pollutant-free home environment to reduce respiratory irritation and susceptibility to infection. Breastfeeding should be strongly encouraged whenever possible, as breast milk provides immunological benefits that enhance the infant's defense against pathogens. Educating parents about recognizing early signs of respiratory distress, such as increased work of breathing, poor feeding, or cyanosis, empowers them to seek timely medical attention. Patient education should be ongoing and tailored to the family's environment, access to care, and understanding, reinforcing preventive measures, promoting healthy practices, and ensuring prompt recognition and management of potential complications. Through consistent guidance and support, clinicians can significantly reduce the burden of bronchiolitis and improve outcomes for vulnerable infants [23].

Other Issues

Bronchiolitis is a viral lower respiratory tract infection characterized by inflammation and obstruction of the small airways, primarily affecting infants and young children under two years of age. The highest incidence occurs between two and six months, a period during which infants are particularly vulnerable to viral infections due to immature immune responses. Respiratory syncytial virus (RSV) is the predominant causative agent, though other viruses, including human metapneumovirus, parainfluenza virus, rhinovirus, adenovirus, influenza, and SARS-CoV-2, have been implicated in the pathogenesis of the disease. The presentation typically begins with nonspecific upper respiratory symptoms, such as nasal congestion, rhinorrhea, and cough, which may initially resemble a common cold. As the disease progresses, clinical manifestations often involve the lower respiratory tract, resulting in tachypnea, wheezing, intercostal retractions, nasal flaring, and hypoxemia. Severe cases may present with poor feeding, lethargy, cyanosis, and other signs of respiratory distress, including grunting and abdominal breathing, which indicate a high risk for respiratory failure. Diagnosis is primarily clinical, based on a comprehensive patient history and thorough physical examination. Viral testing is generally reserved for hospitalized infants to guide infection control measures and appropriate cohorting, rather than for routine outpatient management. Treatment is mainly supportive, focusing on maintaining hydration, clearing airway secretions via nasal suctioning, and providing supplemental oxygen for hypoxemia. Routine administration of glucocorticoids or antibiotics is not recommended, as these interventions have not been shown to improve outcomes in typical viral bronchiolitis. Antiviral therapies, such as oseltamivir

for influenza and nirmatrelvir-ritonavir for SARS-CoV-2, may be indicated when a specific viral etiology is identified, particularly in high-risk populations. Preventive strategies have evolved, with maternal RSV vaccination recommended during pregnancy to confer passive immunity to the infant, and Nirsevimab, a long-acting monoclonal antibody, advised for administration during the infant's first RSV season if maternal vaccination has not been performed [21][22][23]. General measures, including rigorous hand hygiene, minimizing contact with individuals showing respiratory symptoms, and maintaining a smoke-free and pollutant-free environment, are essential in reducing transmission risk. Infants born prematurely or with underlying cardiac, pulmonary, or immunodeficiency disorders are at higher risk for severe disease and complications, requiring careful monitoring. Radiographic imaging is rarely indicated but may reveal nonspecific findings, such as hyperinflation or peribronchial thickening, when performed. Collectively, understanding these aspects of bronchiolitis informs both acute management and preventive strategies, optimizing outcomes in this vulnerable population.

Enhancing Healthcare Team Outcomes

Effective management of bronchiolitis requires a coordinated, interprofessional team approach. Optimal outcomes depend on the collaboration of emergency department physicians, nurse practitioners, pediatric nurses, infectious disease specialists, and primary care providers. Although most children recover with supportive care alone, timely recognition of severe disease and appropriate escalation of care are critical responsibilities shared across the healthcare team. Each team member contributes unique expertise, from initial assessment and triage to ongoing monitoring and parental education. Supporting the infant's nutritional status is a key component of management. Breastfeeding has been demonstrated to reduce the risk of respiratory infections and provides immunologic benefits that may mitigate the severity of viral illnesses. Healthcare providers should actively encourage breastfeeding and provide guidance on maintaining adequate hydration and nutrition during periods of illness. In the hospital setting, strict infection control measures are essential to limit nosocomial transmission. Since bronchiolitis is transmitted through respiratory droplets, contact isolation precautions, including diligent handwashing, use of hand sanitizer, and wearing gowns, gloves, and masks, are recommended. The consistent application of these precautions when entering and exiting patient rooms significantly reduces the risk of transmission among hospitalized infants [24][25].

Most children improve spontaneously within several days, and only a minority require hospitalization. For those admitted, close monitoring of respiratory status, oxygen saturation, and feeding tolerance is critical. Early intervention by the healthcare team can prevent deterioration and minimize complications. Preventive strategies should begin prenatally or at birth, with discussions on infection prevention incorporated into routine prenatal care. Environmental measures, such as avoiding exposure to tobacco smoke and maintaining a clean, smoke-free home, are essential to reduce the risk of severe respiratory infections. Vaccination plays a central role in prevention. Infants older than six months should receive age-appropriate immunizations against influenza and SARS-CoV-2. For infants younger than six months, vaccination of household members and caregivers is crucial to provide indirect protection. The interdisciplinary team also plays a critical role in reinforcing preventive measures. Counseling should occur in multiple settings, including office visits, the emergency department, and during hospital stays. Providing educational materials in the family's native language enhances understanding and adherence to recommendations. Consistency in communication among all members of the healthcare team ensures that parents receive clear, coherent guidance, which improves adherence to preventive measures and increases overall family satisfaction. By combining clinical care, education, infection control, and preventive strategies, healthcare teams can significantly improve outcomes for infants with bronchiolitis while reducing the risk of transmission within the community [24][25].

Conclusion:

Bronchiolitis remains a major global pediatric health concern, particularly affecting infants under two years of age and resulting in substantial seasonal healthcare utilization. Although typically self-limiting, the disease can progress rapidly in high-risk infants, necessitating close monitoring and timely supportive care. Evidence highlights the central role of viral agents—especially RSV—and emphasizes clinical assessment as the cornerstone of diagnosis. Supportive management, including hydration, secretion clearance, and oxygen supplementation, continues to offer the greatest clinical benefit, while unnecessary imaging and pharmacologic interventions should be avoided. Recent advances in maternal RSV vaccination and long-acting monoclonal antibodies have strengthened prevention strategies and demonstrated effectiveness in reducing severe disease, hospitalization, and complications. Ultimately, optimal outcomes depend on early recognition, targeted preventive measures, and coordinated interprofessional care. Continued education for caregivers and adherence to vaccination guidelines remain essential in reducing morbidity and improving respiratory health in vulnerable infants.

References:

1. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EAF, Campbell H, Pariente AB, Bardach D, Bassat Q, Casalegno JS, Chakhunashvili G, Crawford N,

Danilenko D, Do LAH, Echavarria M, Gentile A, Gordon A, Heikkinen T, Huang QS, Jullien S, Krishnan A, Lopez EL, Markić J, Mira-Iglesias A, Moore HC, Moyes J, Mwananyanda L, Nokes DJ, Noordeen F, Obodai E, Palani N, Romero C, Salimi V, Satav A, Seo E, Shchomak Z, Singleton R, Stolyarov K, Stoszek SK, von Gottberg A, Wurzel D, Yoshida LM, Yung CF, Zar HJ, Respiratory Virus Global Epidemiology Network. Nair H., RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May 28;399(10340):2047-2064.

2. Remien KA, Amarin JZ, Horvat CM, Nofziger RA, Page-Goertz CK, Besunder JB, Potts BK, Forbes ML, Halasa N, Pelletier JH. Admissions for Bronchiolitis at Children's Hospitals Before and During the COVID-19 Pandemic. JAMA Netw Open. 2023 Oct 02;6(10):e2339884.
3. Dalziel SR, Haskell L, O'Brien S, Borland ML, Plint AC, Babl FE, Oakley E. Bronchiolitis. Lancet. 2022 Jul 30;400(10349):392-406.
4. Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet. 2017 Jan 14;389(10065):211-224.
5. Yusuf S, Piedimonte G, Auais A, Demmler G, Krishnan S, Van Caeseele P, Singleton R, Broor S, Parveen S, Avendano L, Parra J, Chavez-Bueno S, Murguía De Sierra T, Simoes EA, Shaha S, Welliver R. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect. 2007 Oct;135(7):1077-90.
6. Teoh Z, Conrey S, McNeal M, Burrell A, Burke RM, Mattison CP, McMorrow M, Thornburg N, Payne DC, Morrow AL, Staat MA. Factors Associated With Prolonged Respiratory Virus Detection From Polymerase Chain Reaction of Nasal Specimens Collected Longitudinally in Healthy Children in a US Birth Cohort. J Pediatric Infect Dis Soc. 2024 Mar 19;13(3):189-195.
7. Checchia PA, Paes B, Bont L, Manzoni P, Simões EA, Fauroux B, Figueras-Aloy J, Carbonell-Estrany X. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease. Infect Dis Ther. 2017 Mar;6(1):37-56.
8. Nenna R, Cutrera R, Frassanito A, Alessandroni C, Nicolai A, Cangiano G, Petrarca L, Arima S, Caggiano S, Ullmann N, Papoff P, Bonci E, Moretti C, Midulla F. Modifiable risk factors associated with bronchiolitis. Ther Adv Respir Dis. 2017 Oct;11(10):393-401.
9. Riikonen R, Korppi M, Törmänen S, Koponen P, Nuolivirta K, Helminen M, He Q, Lauhkonen E. Risk factors for irreversible airway obstruction after infant bronchiolitis. Respir Med. 2021 Oct;187:106545.
10. Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DS, Todd JK, Simoes EA. Effect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics. 2006 Feb;117(2):349-56.
11. Nicholson EG, Schlegel C, Garofalo RP, Mehta R, Scheffler M, Mei M, Piedra PA. Robust Cytokine and Chemokine Response in Nasopharyngeal Secretions: Association With Decreased Severity in Children With Physician Diagnosed Bronchiolitis. J Infect Dis. 2016 Aug 15;214(4):649-55.
12. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007 Jan;20(1):108-19.
13. Sebina I, Phipps S. The Contribution of Neutrophils to the Pathogenesis of RSV Bronchiolitis. Viruses. 2020 Jul 27;12(8)
14. Johansson C, Kirsebom FCM. Neutrophils in respiratory viral infections. Mucosal Immunol. 2021 Jul;14(4):815-827.
15. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014 Dec;35(12):519-30.
16. Horvat CM, Pelletier J. A Trial of Albuterol Should Still Be Considered for Children With Severe Bronchiolitis. JAMA Pediatr. 2021 Nov 01;175(11):1182-1183.
17. Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS, McMorrow ML. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 25;72(34):920-925.
18. Törmänen S, Lauhkonen E, Riikonen R, Koponen P, Huhtala H, Helminen M, Korppi M, Nuolivirta K. Risk factors for asthma after infant bronchiolitis. Allergy. 2018 Apr;73(4):916-922.
19. Hon KL, Leung AKC, Wong AHC, Dudi A, Leung KKY. Respiratory Syncytial Virus is the Most Common Causative Agent of Viral Bronchiolitis in Young Children: An Updated Review. Curr Pediatr Rev. 2023;19(2):139-149.
20. Ghazaly MMH, Abu Faddan NH, Raafat DM, Mohammed NA, Nadel S. Acute viral bronchiolitis as a cause of pediatric acute respiratory distress syndrome. Eur J Pediatr. 2021 Apr;180(4):1229-1234.
21. Abreo A, Wu P, Donovan BM, Ding T, Gebretsadik T, Huang X, Stone CA, Turi KN, Hartert TV. Infant Respiratory Syncytial Virus Bronchiolitis and Subsequent Risk of Pneumonia, Otitis Media, and Antibiotic Utilization. Clin Infect Dis. 2020 Jun 24;71(1):211-214.

22. Jerkic SP, Brinkmann F, Calder A, Casey A, Dishop M, Griese M, Kurland G, Niemitz M, Nyilas S, Schramm D, Schubert R, Tamm M, Zielen S, Rosewich M. Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report. Can Respir J. 2020;2020:5852827.
23. Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. Mortality Associated With Respiratory Syncytial Virus, Bronchiolitis, and Influenza Among Infants in the United States: A Birth Cohort Study From 1999 to 2018. J Infect Dis. 2022 Aug 15;226(Suppl 2):S246-S254.
24. Luo G, Stone BL, Nkoy FL, He S, Johnson MD. Predicting Appropriate Hospital Admission of Emergency Department Patients with Bronchiolitis: Secondary Analysis. JMIR Med Inform. 2019 Jan 22;7(1):e12591.
25. Slain KN, Rotta AT, Martinez-Schlurmann N, Stormorken AG, Shein SL. Outcomes of Children With Critical Bronchiolitis Meeting at Risk for Pediatric Acute Respiratory Distress Syndrome Criteria. Pediatr Crit Care Med. 2019 Feb;20(2):e70-e76.